AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy

AI Briefing

• – AGAMREE (vamorolone) has shown comparable long-term effectiveness for up to 8 years of treatment in Duchenne Muscular Dystrophy, with clinically meaningful safety advantages.
• – Results from the ongoing GUARDIAN study were presented at the MDA Clinical & Scientific Conference 2026.
• – Santhera Pharmaceuticals announced the presentation of full results from the long-term real-world comparative analyses of AGAMREE (vamorolone) at the conference.